AI assistant
ARTRYA LIMITED — Share Issue/Capital Change 2025
Aug 24, 2025
64483_rns_2025-08-24_27b954cd-f190-4a14-98d4-1062b89b45ba.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Coronary Artery Disease. We see you.
==> picture [596 x 14] intentionally omitted <==
==> picture [108 x 20] intentionally omitted <==
Issue of Shares on Exercise of Options
PERTH, Australia, 25 August 2025: Artrya Limited (ASX: AYA) ( Artrya or the Company ), a medical technology company commercialising its Salix[®] AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, advises that 1,000,000 ordinary shares were issued today on the exercise of unlisted options.
An Appendix 2A seeking quotation of the shares will be lodged following this announcement.
Attached is a cleansing notice issued in respect of the issue of shares.
- Ends -
This ASX Announcement is authorised for release by the Board of Artrya Limited.
About Artrya
Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to Identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through Innovative technology, with regulatory and commercial activities underway across key international markets.
For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya
For more information:
Corporate Enquiries
Investor & Media Enquiries
John Konstantopoulos Co-Founder and Chief Executive Officer Tel: +61 8 6478 7816 Email: [email protected]
David Allen or John Granger Hawkesbury Partners Tel: +61 499 100 038 or +61 410 577 155 Email: [email protected]
Artrya Limited I ACN 624 005 741 I 1257 Hay Street, West Perth Western Australia 6872 AUSTRALIA www.artrya.com
Coronary Artery Disease. We see you.
==> picture [596 x 14] intentionally omitted <==
==> picture [108 x 20] intentionally omitted <==
SECONDARY TRADING NOTICE – NOTIFICATION PURSUANT
TO PARAGRAPH 708A(5)(E) OF THE CORPORATIONS ACT 2001
PERTH, Australia, 25 August 2025: Artrya Limited (ASX: AYA) ( Artrya or the Company ), a medical technology company commercialising its Salix[®] AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, provides this notice in accordance with section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) in relation to an issue today of 1,000,000 fully paid ordinary shares by Artrya on the exercise of unlisted options.
-
The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
-
As at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and sections 674 and 674A of the Corporations Act.
-
As at the date of this notice, there is no excluded information (in accordance with the requirements of subsections 708A(7) and (8) of the Corporations Act.
- Ends -
This ASX Announcement is authorised for release by the Board of Artrya Limited.
About Artrya
Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to Identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through Innovative technology, with regulatory and commercial activities underway across key international markets.
For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya
For more information:
Corporate Enquiries
Investor & Media Enquiries
John Konstantopoulos Co-Founder and Chief Executive Officer Tel: +61 8 6478 7816 Email: [email protected]
David Allen or John Granger Hawkesbury Partners Tel: +61 499 100 038 or +61 410 577 155 Email: [email protected]
Artrya Limited I ACN 624 005 741 I 1257 Hay Street, West Perth Western Australia 6872 AUSTRALIA www.artrya.com